» Articles » PMID: 36297411

Synthesis and Chemopreventive Potential of 5-FU/Genistein Hybrids on Colorectal Cancer Cells

Overview
Publisher MDPI
Specialty Chemistry
Date 2022 Oct 27
PMID 36297411
Authors
Affiliations
Soon will be listed here.
Abstract

A series of 5-FU-Genistein hybrids were synthesized and their structures were elucidated by spectroscopic analysis. The chemopreventive potential of these compounds was evaluated in human colon adenocarcinoma cells (SW480 and SW620) and non-malignant cell lines (HaCaT and CHO-K1). Hybrid displayed cytotoxicity against SW480 and SW620 cells with IC values of 62.73 ± 7.26 µM and 50.58 ± 1.33 µM, respectively; compound induced cytotoxicity in SW620 cells with an IC value of 36.84 ± 0.71 µM. These compounds were even more selective than genistein alone, the reference drug (5-FU) and the equimolar mixture of genistein plus 5-FU. In addition, hybrids and induced time- and concentration-dependent antiproliferative activity and cell cycle arrest at the S-phase and G2/M. It was also observed that hybrid 4a induced apoptosis in SW620 cells probably triggered by the extrinsic pathway in response to the activation of p53, as evidenced by the increase in the levels of caspases 3/8 and the tumor suppressor protein (Tp53). Molecular docking studies suggest that the most active compound would bind efficiently to proapoptotic human caspases 3/8 and human Tp53, which in turn could provide valuable information on the biochemical mechanism for the in vitro cytotoxic response of this compound in SW620 colon carcinoma cell lines. On the other hand, molecular dynamics (MD) studies provided strong evidence of the conformational stability of the complex between caspase-3 and hybrid obtained throughout 100 ns all-atom MD simulation. Molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) analyses of the complex with caspase-3 showed that the interaction between the ligand and the target protein is stable. Altogether, the results suggest that the active hybrids, mainly compound , might act by modulating caspase-3 activity in a colorectal cancer model, making it a privileged scaffold that could be used in future investigations.

Citing Articles

A review on pyrimidine-based pharmacophore as a template for the development of hybrid drugs with anticancer potential.

Sharma S, Babu M, Kumar R, Singh T, Dwivedi A, Ahmad G Mol Divers. 2025; .

PMID: 39937329 DOI: 10.1007/s11030-025-11112-x.


Isoflavone Derivatives as Potential Anticancer Agents: Synthesis and Bioactivity Studies.

Selepe M ChemMedChem. 2024; 19(23):e202400420.

PMID: 39091268 PMC: 11617652. DOI: 10.1002/cmdc.202400420.


Special Issue "Hybrid Drugs: Design and Applications".

Singh P, Kumar V Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895829 PMC: 10610076. DOI: 10.3390/ph16101358.


Synthesis, Characterization, Theoretical and Experimental Anticancer Evaluation of Novel Cocrystals of 5-Fluorouracil and Schiff Bases against SW480 Colorectal Carcinoma.

Jubeen F, Jabeen I, Aftab U, Noor S, Hareem M, Sultan M Pharmaceutics. 2023; 15(7).

PMID: 37514115 PMC: 10383612. DOI: 10.3390/pharmaceutics15071929.


New Hybrid Scaffolds Based on 5-FU/Curcumin: Synthesis, Cytotoxic, Antiproliferative and Pro-Apoptotic Effect.

Moreno-Quintero G, Betancur-Zapata E, Herrera-Ramirez A, Cardona-Galeano W Pharmaceutics. 2023; 15(4).

PMID: 37111708 PMC: 10144058. DOI: 10.3390/pharmaceutics15041221.


References
1.
Xie S, Wang Q, Wu H, Cogswell J, Lu L, Jhanwar-Uniyal M . Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3. J Biol Chem. 2001; 276(39):36194-9. DOI: 10.1074/jbc.M104157200. View

2.
Polkowski K, Popiolkiewicz J, Krzeczynski P, Ramza J, Pucko W, Zegrocka-Stendel O . Cytostatic and cytotoxic activity of synthetic genistein glycosides against human cancer cell lines. Cancer Lett. 2003; 203(1):59-69. DOI: 10.1016/j.canlet.2003.08.023. View

3.
Antosiak A, Milowska K, Maczynska K, Rozalska S, Gabryelak T . Cytotoxic activity of genistein-8-C-glucoside form L. and genistein against human SK-OV-3 ovarian carcinoma cell line. Med Chem Res. 2017; 26(1):64-73. PMC: 5219005. DOI: 10.1007/s00044-016-1725-5. View

4.
Selivanova G, Wiman K . Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene. 2007; 26(15):2243-54. DOI: 10.1038/sj.onc.1210295. View

5.
Bozorov K, Zhao J, Aisa H . 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview. Bioorg Med Chem. 2019; 27(16):3511-3531. PMC: 7185471. DOI: 10.1016/j.bmc.2019.07.005. View